Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biologic therapy for inflammatory bowel disease comes of age.

Literature DB >> 18377800

Biologic therapy for inflammatory bowel disease comes of age.

Stephen B Hanauer.

Abstract

Entities: Chemical

Year: 2007 PMID： 18377800

Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN： 1522-8037

Keyword Cloud
References

× No keyword cloud information.

21 in total

1. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

Authors: Stephen B Hanauer; Carrie L Wagner; Mohan Bala; Lloyd Mayer; Suzanne Travers; Robert H Diamond; Allan Olson; Warren Bao; Paul Rutgeerts
Journal: Clin Gastroenterol Hepatol Date: 2004-07 Impact factor: 11.382

2. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.

Authors: Joel R Rosh; Maria Oliva-Hemker
Journal: J Pediatr Gastroenterol Nutr Date: 2007-02 Impact factor: 2.839

3. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors: Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal: J Pediatr Gastroenterol Nutr Date: 2007-02 Impact factor: 2.839

4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors: Stephen B Hanauer
Journal: Gut Date: 2007-09 Impact factor: 23.059

5. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors: Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal: Gastroenterology Date: 2006-11-29 Impact factor: 22.682

6. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.

Authors: Paul Rutgeerts; Robert H Diamond; Mohan Bala; Allan Olson; Gary R Lichtenstein; Weihang Bao; Kamlesh Patel; Douglas C Wolf; Michael Safdi; Jean Frederic Colombel; Bret Lashner; Stephen B Hanauer
Journal: Gastrointest Endosc Date: 2006-03 Impact factor: 9.427

Biologic therapy for inflammatory bowel disease comes of age.

1. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

2. Infliximab use and hepatosplenic T cell lymphoma: questions to be asked and lessons learned.

3. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

4. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

5. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

6. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.

7. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.

Review 8. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

9. Certolizumab pegol for the treatment of Crohn's disease.

10. Maintenance therapy with certolizumab pegol for Crohn's disease.